1196 related articles for article (PubMed ID: 17161777)
1. Antihypertensive drugs and fibrinolytic function.
Fogari R; Zoppi A
Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
[TBL] [Abstract][Full Text] [Related]
2. Effects of lisinopril, irbesartan, and amlodipine on the thrombogenic variables in the early and late stages of the treatment in hypertensive patients.
Tiryaki O; Usalan C; Buyukhatipoglu H; Sayiner ZA; Kilisli H
Clin Exp Hypertens; 2012; 34(2):145-52. PubMed ID: 21967026
[TBL] [Abstract][Full Text] [Related]
3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of ACE inhibitors versus AT1 blockers.
Vaughan D
Can J Cardiol; 2000 Aug; 16 Suppl E():36E-40E. PubMed ID: 10906625
[TBL] [Abstract][Full Text] [Related]
5. [Antihypertensive therapy for refractory morning hypertension in patients on peritoneal dialysis].
Kuriyama S; Otsuka Y; Iida R; Kobayashi S; Yamagishi H; Hosoya T
Nihon Jinzo Gakkai Shi; 2005; 47(1):38-45. PubMed ID: 15754762
[TBL] [Abstract][Full Text] [Related]
6. [Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].
Boucek P
Vnitr Lek; 2006 Sep; 52(9):791-6. PubMed ID: 17091602
[TBL] [Abstract][Full Text] [Related]
7. Blood pressure reduction is not the only determinant of outcome.
Sever PS; Poulter NR; Elliott WJ; Jonsson MC; Black HR; Sever PS; Poulter NR; Elliott WJ; Jonsson MC; Black HR
Circulation; 2006 Jun; 113(23):2754-72; discussion 2773-4. PubMed ID: 16769926
[No Abstract] [Full Text] [Related]
8. The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm.
Schmieder RE
Clin Exp Hypertens; 2010 Jan; 32(1):35-42. PubMed ID: 20144071
[TBL] [Abstract][Full Text] [Related]
9. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
Weir MR
J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800
[TBL] [Abstract][Full Text] [Related]
10. Endocrine arterial hypertension: therapeutic approach in clinical practice.
Mazza A; Armigliato M; Zamboni S; Rempelou P; Rubello D; Pessina AC; Casiglia E
Minerva Endocrinol; 2008 Dec; 33(4):297-312. PubMed ID: 18923367
[TBL] [Abstract][Full Text] [Related]
11. [Are all antihypertensive drugs renoprotective?].
Wolf S; Risler T
Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
[TBL] [Abstract][Full Text] [Related]
12. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
Tiryaki O; Usalan C; Buyukhatipoglu H
Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
[TBL] [Abstract][Full Text] [Related]
13. Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease.
Mizuno Y; Jacob RF; Mason RP
Am J Hypertens; 2008 Oct; 21(10):1076-85. PubMed ID: 18756260
[TBL] [Abstract][Full Text] [Related]
14. Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner.
Roberts ME; Epstein BJ
J Cardiovasc Nurs; 2009; 24(5):380-9. PubMed ID: 19707098
[TBL] [Abstract][Full Text] [Related]
15. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients.
Hillebrand U; Suwelack BM; Loley K; Lang D; Reuter S; Amler S; Pavenstädt H; Hausberg M; Büssemaker E
Transpl Int; 2009 Nov; 22(11):1073-80. PubMed ID: 19624495
[TBL] [Abstract][Full Text] [Related]
16. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system.
de la Sierra A
J Hum Hypertens; 2009 Aug; 23(8):503-11. PubMed ID: 19148104
[TBL] [Abstract][Full Text] [Related]
17. Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring.
Karotsis AK; Symeonidis A; Mastorantonakis SE; Stergiou GS;
Clin Exp Hypertens; 2006 Oct; 28(7):655-62. PubMed ID: 17060064
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive drug treatment and fibrinolytic function.
Lottermoser K; Weisser B; Hertfelder HJ; Wöstmann B; Vetter H; Düsing R
Am J Hypertens; 1998 Mar; 11(3 Pt 1):378-84. PubMed ID: 9544880
[TBL] [Abstract][Full Text] [Related]
19. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
Liu L; Zhao SP; Zhou HN; Li QZ; Li JX
J Cardiovasc Pharmacol; 2007 Jul; 50(1):50-5. PubMed ID: 17666915
[TBL] [Abstract][Full Text] [Related]
20. A dynamic comparative study concerning the effects of angiotensin-converting enzyme inhibitors and aldosterone receptor blockers on the fibrinolytic system.
Usalan C; Buyukhatipoglu H
Clin Appl Thromb Hemost; 2008 Apr; 14(2):203-9. PubMed ID: 18372278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
